Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.


Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, 11000, Thailand. idweerawat@yahoo.com

Seventy human immunodeficiency virus (HIV)-infected patients receiving rifampicin and 70 HIV-infected patients not receiving rifampicin were enrolled to receive 400 mg of nevirapine-based highly active antiretroviral therapy per day. Mean plasma nevirapine levels at 8 and 12 weeks were lower in patients receiving rifampicin (P=.048). However, virological and immunological outcomes at 24 weeks were not different between the 2 groups (P>.05).

PMID: 16779754 [PubMed - in process]

Related Links:

Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. [AIDS. 2005] PMID:16135901

Lopinavir/ritonavir: a review of its use in the management of HIV infection. [Drugs. 2003] PMID:12662125


Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. [HIV Clin Trials. 2002] PMID:12032876

Stavudine plus didanosine and nevirapine in antiretroviral-naïve HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team. [Antivir Ther. 1998] PMID:10723512